Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005) |
OMB No. 0651-0054 (Exp 12/31/2020) |
Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))
The table below presents the data as entered.
Input Field
|
Entered
|
SERIAL NUMBER |
88155213 |
LAW OFFICE ASSIGNED |
LAW OFFICE 104 |
MARK SECTION |
MARK |
MYMELDI (see, http://uspto.report/TM/88155213/mark.png) |
STANDARD CHARACTERS |
YES |
USPTO-GENERATED IMAGE |
YES |
LITERAL ELEMENT |
MYMELDI |
OWNER SECTION (current) |
NAME |
ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED |
MAILING ADDRESS |
CLONSHAUGH BUSINESS and TECHNOLOGY PARK |
CITY |
COOLOCK, DUBLIN |
ZIP/POSTAL CODE |
D17E400 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
Ireland |
PHONE |
714-246-5351 |
EMAIL |
XXXX |
OWNER SECTION (proposed) |
NAME |
ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED |
MAILING ADDRESS |
CLONSHAUGH BUSINESS and TECHNOLOGY PARK |
CITY |
COOLOCK, DUBLIN |
ZIP/POSTAL CODE |
D17E400 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
Ireland |
PHONE |
714-246-5351 |
EMAIL |
XXXX |
CORRESPONDENCE INFORMATION (current) |
NAME |
Matthew O. Brady |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE |
Matthew.Brady@Allergan.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) |
kent_alexander@allergan.com |
CORRESPONDENCE INFORMATION (proposed) |
NAME |
Matthew O. Brady |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE |
Matthew.Brady@Allergan.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) |
kent_alexander@allergan.com |
GOODS AND/OR SERVICES SECTION |
INTERNATIONAL CLASS |
005 |
CURRENT IDENTIFICATION |
Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles,
asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics,
anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical
preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonia, smooth muscle
disorders, autonomic nerve disorders, headaches, hyperhidrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams,
acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement
therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive
bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical
preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating
pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical
preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations
and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines
for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders;
Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or
which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment
of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and
neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of
neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and
treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and
treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals,
namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated
skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body |
GOODS OR SERVICES |
KEEP ALL LISTED |
EXTENSION SECTION |
EXTENSION NUMBER |
3 |
ONGOING EFFORT |
product or service research or development ; market research |
ALLOWANCE MAIL DATE |
04/30/2019 |
STATEMENT OF USE |
NO |
PAYMENT SECTION |
NUMBER OF CLASSES |
1 |
SUBTOTAL AMOUNT [EXTENSION FEE] |
125 |
TOTAL AMOUNT |
125 |
SIGNATURE SECTION |
SIGNATURE |
/mob/ |
SIGNATORY'S NAME |
Matthew O. Brady |
SIGNATORY'S POSITION |
Attorney of Record |
DATE SIGNED |
10/02/2020 |
SIGNATORY'S PHONE NUMBER |
714-246-4788 |
FILING INFORMATION |
SUBMIT DATE |
Fri Oct 02 21:06:04 ET 2020 |
TEAS STAMP |
USPTO/ESU-XXXX:XXXX:XXXX:
XX:XXXX:XXXX:XXXX:XXXX-20
201002210604141840-881552
13-75052181cc1bc1a83984c6
0e64ad9ded1b6565b58d8dc5e
4a294bd789e44f47eb-DA-060
39467-2020100221040318393
0 |
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005) |
OMB No. 0651-0054 (Exp 12/31/2020) |
SOU Extension Request
(15 U.S.C. Section 1051(d))
To the Commissioner for Trademarks:
MARK: MYMELDI (see, http://uspto.report/TM/88155213/mark.png)
SERIAL NUMBER: 88155213
OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED, having an address of
CLONSHAUGH BUSINESS and TECHNOLOGY PARK
COOLOCK, DUBLIN, D17E400
Ireland
Phone: 714-246-5351
Email: XXXX
Proposed: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED, having an address of
CLONSHAUGH BUSINESS and TECHNOLOGY PARK
COOLOCK, DUBLIN, D17E400
Ireland
Phone: 714-246-5351
Fax:
Email: XXXX
The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application. The Notice of Allowance mailing date was 04/30/2019.
For International Class 005:
Current identification: Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of
the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma
agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular
inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonia, smooth muscle disorders, autonomic nerve disorders, headaches,
hyperhidrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener
lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations
for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the
treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of
endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing
pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory
organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ
disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood
pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for
the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone
disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical
preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical
preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders;
Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system
diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia,
AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating
agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers,
rejuvenators, rehydrating creams, and lotions for the face and body
For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice
of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate
control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this
specific class.
This is the third extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with each of those goods/services covered by the extension
request: product or service research or development ; market research
Correspondence Information (current):
Matthew O. Brady
PRIMARY EMAIL FOR CORRESPONDENCE: Matthew.Brady@Allergan.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): kent_alexander@allergan.com
Correspondence Information (proposed):
Matthew O. Brady
PRIMARY EMAIL FOR CORRESPONDENCE: Matthew.Brady@Allergan.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): kent_alexander@allergan.com
Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all
official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).
A fee payment in the amount of $125 will be submitted with the form, representing payment for 1 class.
Declaration
STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section
1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the
mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of
the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near
resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.
DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and
the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made
on information and belief are believed to be true.
Signature: /mob/ Date Signed: 10/02/2020
Signatory's Name: Matthew O. Brady
Signatory's Position: Attorney of Record
Signatory's Phone: 714-246-4788
RAM Sale Number: 88155213
RAM Accounting Date: 10/02/2020
Serial Number: 88155213
Internet Transmission Date: Fri Oct 02 21:06:04 ET 2020
TEAS Stamp: USPTO/ESU-XXXX:XXXX:XXXX:XX:XXXX:XXXX:XX
XX:XXXX-20201002210604141840-88155213-75
052181cc1bc1a83984c60e64ad9ded1b6565b58d
8dc5e4a294bd789e44f47eb-DA-06039467-2020
1002210403183930